FENG Bo, ZHAO Caijun, CHANG Liguo. Dual Antiplatelet Therapy for Acute Minor Ischemic Stroke in Loss-of-function Carriers Based on Rapid CYP2C19 Genotyping: A Case Report[J]. Chinese Journal of Stroke, 2022, 17(08): 817-820.
[1]VON WEITZEL-MUDERSBACH P，ANDERSEN G，HUNDBORG H H，et al. Transient ischemic attack and minor stroke are the most common manifestations of acute cerebrovascular disease：a prospective，population-based study-the Aarhus TIA study[J]. Neuroepidemiology，2013，40（1）：50-55.
[2]王伊龙，赵性泉，刘新峰，等. 高危非致残性缺血性脑血管事件诊疗指南[J]. 中国卒中杂志，2016，11（6）：481-491.
[3]OIS A，GOMIS M，RODRIGUEZ-CAMPELLO A，et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke[J]. Stroke，2008，39（6）：1717-1721.
[4]WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[5]中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J]. 中华神经科杂志，2015，48（4）：258-273.
[6]KAZUI M，NISHIYA Y，ISHIZUKA T，et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[J]. Drug Metab Dispos，2010，38（1）：92-99.
[7]OLIPHANT C S，TREVARROW B J，DOBESH P P. Clopidogrel response variability：review of the literature and practical considerations[J]. J Pharm Pract，2016，29（1）：26-34.
[8]ANGIOLILLO D J，FERNANDEZ-ORTIZ A，BERNARDO E，et al. Variability in individual responsiveness to clopidogrel：clinical implications. management，and future perspectives[J]. J Am Coll Cardiol，2007，49（14）：1505-1516.
[9]LIU R，ZHOU Z Y，CHEN Y B，et al. Associations of CYP3A4，NR112，CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke[J]. Acta Pharmacol Sin，2016，37（7）：882-888.
[10]WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.
